Shield Diagnostics (UK) goes to market with SyphScreen:
This article was originally published in Clinica
Shield Diagnostics (UK) has launched SyphScreen EIA, a test for the primary screening of syphilis. Shield says recent trials on 10,000 samples showed the test to have a sensitivity of 100% and a specificity of 97.3%.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.